Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Kymera Therapeutics, Inc.: Strengths and Weaknesses

Highlights: Kymera Therapeutics, Inc.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: Kymera Therapeutics, Inc.
  • Low profitability weakens the company.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The group usually releases earnings worse than estimated.

Rating Financials

Kymera Therapeutics, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Kymera Therapeutics, Inc. SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Kymera Therapeutics, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Kymera Therapeutics, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Kymera Therapeutics, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
6.76B -
BBB
- -
41.67B
AAA
32.6B -
30.97B -
B
- -
28.23B
AAA
26.41B
A
14.94B - - - - -
14.13B - - - - - - -
12.27B -
A
- -
12.12B
AA
Average 22.01B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. Ratings Kymera Therapeutics, Inc.